Clinical news & media

05/07/2023 - Press releases

Medimaps Group deep-tech TBS software endorsed by international experts working group to inform osteoporosis management decisions for the benefit of the patient

01/06/2023 - Press articles

Radiology Today: “Breaking the silence on bone conditions”

01/03/2023 - Press articles

Inside Precision Medicine: “AI-based algorithm could improve osteoporosis diagnosis and monitoring”

01/03/2023 - Press releases

Medimaps Group presents data showing new AI approach enhances osteoporosis diagnosis and monitoring at ECR 2023

01/12/2022 - Press articles

AARP Magazine: “Osteoporosis: know your risks, test your bones”

28/11/2022 - Press releases

Medimaps Group appoints Meinhard F. Schmidt as Board Chairman; adds Anne Le Grand and five additional board members

14/11/2022 - Press releases

Medimaps Group announces partnership with OsteoSys to bring trabecular bone score to Korea’s leading bone densitometry platform

04/03/2022 - Press releases

Medical reimbursement now available for trabecular bone score (TBS), an advanced medtech solution with artificial intelligence capabilities, for osteoporosis fracture risk assessment

01/01/2021 - Press releases

Medimaps Group raises $20 million to expand and to commercialize AI product portfolio for bone health assessment utilizing routine medical images

1 2 3

medimaps group SA
Chemin du Champ-des-Filles 36A
1228 Plan-les-Ouates
Geneva, Switzerland

Medimaps Group USA LLC
1201N Market Street
Suite 111
Wilmington, DE 19801, United States

Customer care

Medimaps Group has been certified by DNV to ISO 13485:2016 under certificate number MDR C831120 CE 2460. TBS iNsight and TBS Reveal are trademarks of Medimaps Group. TBS iNsight is cleared for sale in the US.